AVIR Atea Pharmaceuticals Inc

USD 2.96 +0.07 ( +2.42%)
Icon

Atea Pharmaceuticals Inc (AVIR) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 2.96

+0.07 (+2.42%)

USD 0.25B

0.22M

USD 6.00(+102.70%)

USD 78.00 (+2535.14%)

Icon

AVIR

Atea Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 2.96
+0.07 ( +2.42%)
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.25B

USD 78.00 (+2535.14%)

USD 2.96

Atea Pharmaceuticals Inc (AVIR) Stock Forecast

Show ratings and price targets of :
USD 6.00
(+102.70%)

Based on the Atea Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Atea Pharmaceuticals Inc is USD 6.00 over the next 12 months. Atea Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Atea Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Atea Pharmaceuticals Inc’s stock price was USD 2.96. Atea Pharmaceuticals Inc’s stock price has changed by +3.50% over the past week, +1.02% over the past month and -20.22% over the last year.

No recent analyst target price found for Atea Pharmaceuticals Inc
No recent average analyst rating found for Atea Pharmaceuticals Inc

Company Overview Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruz...Read More

https://ateapharma.com

225 Franklin Street, Boston, MA, United States, 02110

56

December

USD

USA

Adjusted Closing Price for Atea Pharmaceuticals Inc (AVIR)

Loading...

Unadjusted Closing Price for Atea Pharmaceuticals Inc (AVIR)

Loading...

Share Trading Volume for Atea Pharmaceuticals Inc Shares

Loading...

Compare Performance of Atea Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AVIR

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Atea Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +2.65 (+0.54%) USD126.52B 32.57 251.19

Frequently Asked Questions About Atea Pharmaceuticals Inc (AVIR) Stock

Based on ratings from 1 analysts Atea Pharmaceuticals Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on AVIR's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for AVIR is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.

AVIR stock's Price/Earning ratio is 9.85. Our analysis grades AVIR stock's Price / Earning ratio at F. This means that AVIR stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange. Based on this AVIR may be a overvalued for its sector.

The last closing price of AVIR's stock was USD 2.96.

The most recent market capitalization for AVIR is USD 0.25B.

Based on targets from 1 analysts, the average taret price for AVIR is projected at USD 6.00 over the next 12 months. This means that AVIR's stock price may go up by +102.70% over the next 12 months.

We can't find any ETFs which contains Atea Pharmaceuticals Inc's stock.

As per our most recent records Atea Pharmaceuticals Inc has 56 Employees.

Atea Pharmaceuticals Inc's registered address is 225 Franklin Street, Boston, MA, United States, 02110. You can get more information about it from Atea Pharmaceuticals Inc's website at https://ateapharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Frequently Asked Questions About Atea Pharmaceuticals Inc (AVIR) Stock

Based on ratings from 1 analysts Atea Pharmaceuticals Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on AVIR's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for AVIR is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.

AVIR stock's Price/Earning ratio is 9.85. Our analysis grades AVIR stock's Price / Earning ratio at F. This means that AVIR stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange. Based on this AVIR may be a overvalued for its sector.

The last closing price of AVIR's stock was USD 2.96.

The most recent market capitalization for AVIR is USD 0.25B.

Based on targets from 1 analysts, the average taret price for AVIR is projected at USD 6.00 over the next 12 months. This means that AVIR's stock price may go up by +102.70% over the next 12 months.

We can't find any ETFs which contains Atea Pharmaceuticals Inc's stock.

As per our most recent records Atea Pharmaceuticals Inc has 56 Employees.

Atea Pharmaceuticals Inc's registered address is 225 Franklin Street, Boston, MA, United States, 02110. You can get more information about it from Atea Pharmaceuticals Inc's website at https://ateapharma.com.
Loading...